The short version of actin binding fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-09-16 and is reviewed periodically as new material appears.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H68N10O14 | Acetylated heptapeptide form |
| Monoisotopic mass | 888.5 Da | Average mass about 889 Da |
| Appearance | White to off-white solid | Usually supplied as lyophilised powder |
| Solubility class | Highly water soluble | Also dissolves in aqueous buffers |
| Common synonyms | Tbeta4 fragment, thymosin beta-4 (17-23) | Refer to the same sequence |
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
The efficacy of dapagliflozin to improve kidney outcomes and reduce cardiovascular death in people with chronic kidney disease was evaluated in a multicenter, double-blind study of 4,304 participants. In February 2023, the EU authorized dapagliflozin for extended use to cover heart failure patients across the full spectrum of left ventricular ejection fraction (LVEF), including those with mildly reduced and preserved ejection fraction.
By binding to nicotinic acetylcholine receptors in the brain, nicotine elicits its psychoactive effects and increases the levels of several neurotransmitters in various brain structures – acting as a sort of "volume control". Nicotine has a higher affinity for nicotinic receptors in the brain than those in skeletal muscle, though at toxic doses it can induce contractions and respiratory paralysis. Nicotine's selectivity is thought to be due to a particular amino acid difference on these receptor subtypes. Nicotine is unusual in comparison to most drugs, as its profile changes from stimulant to sedative with increasing dosages, a phenomenon known as "Nesbitt's paradox" after the doctor who first described it in 1969. At very high doses it dampens neuronal activity. Nicotine induces both behavioral stimulation and anxiety in animals. Research into nicotine's most predominant metabolite, cotinine, suggests that some of nicotine's psychoactive effects are mediated by cotinine. Nicotine activates nicotinic receptors (particularly α4β2 nicotinic receptors, but also α5 nAChRs) on neurons that innervate the ventral tegmental area and within the mesolimbic pathway where it appears to cause the release of dopamine. This nicotine-induced dopamine release occurs at least partially through activation of the cholinergic–dopaminergic reward link in the ventral tegmental area. Nicotine can modulate the firing rate of the ventral tegmental area neurons.
platelet-derived growth factor transforming growth factor beta fibroblast growth factor insulin-like growth factor 1 insulin-like growth factor 2 vascular endothelial growth factor A vascular endothelial growth factor C epidermal growth factor interleukin 8 keratinocyte growth factor connective tissue growth factor hepatocyte growth factor stromal cell-derived factor 1 endostatin
19th century experiments into this luminiferous aether attempted to detect a minute drag on the Earth's orbit. While the Earth does, in fact, move through a relatively dense medium in comparison to that of interstellar space, the drag is so minuscule that it could not be detected. In 1912, astronomer Henry Pickering commented: "While the interstellar absorbing medium may be simply the ether, [it] is characteristic of a gas, and free gaseous molecules are certainly there". Thereafter, however, luminiferous aether was discarded. Later, in 1930, Paul Dirac proposed a model of the vacuum as an infinite sea of particles possessing negative energy, called the Dirac sea. This theory helped refine the predictions of his earlier formulated Dirac equation, and successfully predicted the existence of the positron, confirmed two years later. Werner Heisenberg's uncertainty principle, formulated in 1927, predicted a fundamental limit within which instantaneous position and momentum, or energy and time can be measured. These far-reaching consequences also threatened whether the "emptiness" of space between particles exists.
Sources: en.wikipedia.org
1333: Thomasia de Mattio, Italian physician, mentioned in Pope Sixtus IV edict regarding physicians and surgeons. fl. 1335: Polisena da Troya, licensed Neapolitan surgeon. d. 1366: Jeanne d'Ausshure, French surgeon. fl. 1374: Floreta La-Noga, Aragonese physician. fl. 1376: Virdimura of Catania, Jewish-Sicilian physician. fl. 1380: Bellayne Gallipapa, Zaragoza, Aragonese-Jewish physician. fl. 1384: Dolcich Gallipapa, Lleida, Catalan-Jewish physician. fl. 1384: Juana Sarrovia, Barcelona, Catalan physician. fl. 1387: Na Pla Gallipapa, Zaragoza, Aragonese-Jewish physician. late 13th century: Margherita di Napoli, Napolitan oculist active in Frankfurt-am-Main. fl. 1390: Dorotea Bucca, Italian professor of medicine. 1386–1408: Maesta Antonia, Florentine physician. 14th century: Abella, Italian physician. 14th century: Mercuriade, Italian physician and surgeon. fl. 1400: Antonia Daniello, Florentine-Jewish physician. fl. 13th century: Brunetta de Siena, Italian-Jewish physician. fl. 13th century: Caterina of Florence, Florentine physician. fl. 1411: Peretta Peronne, also called Perretta Petone, French surgeon. fl. 1415: Constance Calenda, Italian surgeon specializing in diseases of the eye. fl. 1438: Jeanne de Cusey, French barber-surgeon. fl. 1460: Marguerite Saluzzi, Napolitan licensed herbalist physician. fl. 1479: Guillemette du Luys, French royal surgeon. d. 1498: Gentile Budrioli (or Gentile Cimieri), Italian astrologer and herbalist. 15th century: Clarice di Durisio, Italian physician. 15th century Francesca, muller de Berenguer Satorra, Catalan physician. c.
The National Economic Council (NEC) in Pakistan is a constitutional entity tasked with evaluating the nation's economic state and devising strategies to promote equitable development and regional balance. Functioning within the framework of Article 156 of the Constitution of Pakistan, it plays a vital advisory role to both federal and provincial governments on matters pertaining to finance, commerce, social welfare, and economic policies.
=== Vaccinations === People with RA have an increased risk of infections and mortality, and recommended vaccinations can reduce these risks. The inactivated influenza vaccine should be received annually. The pneumococcal vaccine should be administered twice for people under the age 65 and once for those over 65. Lastly, the live-attenuated zoster vaccine should be administered once after the age 60, but is not recommended in people on a tumor necrosis factor alpha blocker.
== See also == Fitness (biology) – Expected reproductive success Survival of the fittest – Phrase to describe the mechanism of natural selection Conserved sequence – Similar DNA, RNA or protein sequences within genomes or among species
PGC1-α (PPARGC1A), a transcriptional coactivator of nuclear receptors important to the regulation of a number of mitochondrial genes involved in oxidative metabolism, directly interacts with MEF2 to synergistically activate selective slow twitch (ST) muscle genes and also serves as a target for calcineurin signaling. A peroxisome proliferator-activated receptor δ (PPARδ)-mediated transcriptional pathway is involved in the regulation of the skeletal muscle fiber phenotype. Mice that harbor an activated form of PPARδ display an "endurance" phenotype, with a coordinated increase in oxidative enzymes and mitochondrial biogenesis and an increased proportion of ST fibers. Thus—through functional genomics—calcineurin, calmodulin-dependent kinase, PGC-1α, and activated PPARδ form the basis of a signaling network that controls skeletal muscle fiber-type transformation and metabolic profiles that protect against insulin resistance and obesity. The transition from aerobic to anaerobic metabolism during intense work requires that several systems are rapidly activated to ensure a constant supply of ATP for the working muscles. These include a switch from fat-based to carbohydrate-based fuels, a redistribution of blood flow from nonworking to exercising muscles, and the removal of several of the by-products of anaerobic metabolism, such as carbon dioxide and lactic acid. Some of these responses are governed by transcriptional control of the fast twitch (FT) glycolytic phenotype.
Sources: en.wikipedia.org
No. TB-500 is a short synthetic peptide matching residues 17 to 23 of thymosin beta-4, while the parent protein contains 43 residues. The fragment lacks the rest of the protein sequence, so the two are related but not identical.
It consists of leucine, lysine, lysine, threonine, glutamic acid, threonine, and glutamine in that order. The N-terminal leucine is usually acetylated in the forms described in catalogues.
Controlled human data is limited, and most published findings come from cell culture or animal work. This makes it difficult to state clinical effects with confidence.
TB-500 is a trade-style label for a synthetic peptide connected to thymosin beta-4. It is sold mainly through research-chemical channels and is not a single chemically defined product across suppliers.